Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-? and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-?/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: The present invention provides novel ion channel polypeptides and polynucleotides that identify and encode them. In addition, the invention provides expression vectors, host cells and methods for their production. The invention also provides methods for the identification of ion channel agonists/antagonists, useful for the treatment of human diseases and conditions.

Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.

Abstract: This invention relates to a novel protein, termed LBDG3, herein identified as a Nuclear Hormone Receptor Ligand Binding Domain and to the use of this protein and nucleic acid sequence from the encoding genes in the diagnosis, prevention and treatment of disease.

Abstract: This invention relates to a novel protein, termed BAA22563.1, herein identified as a Nuclear Hormone Receptor Ligand Binding Domain and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.

Abstract: This invention relates to a novel protein, termed BAA74848.1, herein identified as a Nuclear Hormone Receptor Ligand Binding Domain and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: This invention relates to novel proteins, termed BAA31618.1, herein identified as a Nuclear Hormone Receptor Ligand Binding Domain and to the use of this proteins and nucleic acid sequence from the encoding genes in the diagnosis, prevention and treatment of disease.

Abstract: The invention relates to a novel protein, termed BAA07892.2, herein identified as a Nuclear Hormone Receptor Ligand Binding Domain and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: This invention relates to novel proteins, termed AAC74854.1, AAC76768.1 and P10155, herein identified as adhesion molecules and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

Abstract: This invention relates to novel proteins, termed BAA91543.1, herein identified as a Nuclear Hormone Receptor Ligand Binding Domain and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: This application discloses and claims a protein, herein identified as an interferon gamma-like secreted protein of the of the four helical bundle cytokine fold, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: This invention relates to proteins, termed Q14507, CAA53971.2 and CAC17141.1 herein identified as cytokines and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

Abstract: This invention discloses and claims novel proteins, termed KIAA0301, G7c, KIAA0564, NG37, CAB01991.1 and Rv0368c, herein identified as adhesion molecules. Also disclosed and claimed are methods of use of these proteins, and nucleic acid sequences from the encoding genes, in the diagnosis, prevention and treatment of disease.

Abstract: A disclosed method allows service subscribers to modify service subscriptions online. Operations within the method may include receiving an order for a service package from a subscriber, wherein the service package includes multiple features. In response to the order, the features in the service package may automatically be cross referenced with a list of existing features for the subscriber to detect any overlap between the features in the service package and the existing features. In response to detecting an overlap, a subscription change request may automatically be computed, wherein subscription change request includes only the features in the service package that do not overlap the existing features. The subscription change request may then be submitted for implementation by a service provider, possibly after receiving confirmation of the change request from the subscriber.